Company Drug

Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations

By Fineline Cube #Clinical trial approval / initiation #HKG: 9887 #Leads Biolabs #Multi-specific antibodies

Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced first patient enrollment in a Phase II clinical study evaluating opamtistomig (LBL-024), a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in first-line esophageal squamous cell carcinoma (ESCC). The candidate, previously awarded Breakthrough Therapy Designation (BTD) in China and Orphan Drug/Fast Track Designations in the U.S. and EU, has demonstrated first-in-class (FIC) or best-in-class (BIC) potential across three prior indications, positioning Leads Biolabs to address the significant unmet need in one of China’s highest-incidence malignancies.

Clinical Milestone

ItemDetail
Study PhasePhase II
DrugOpamtistomig (LBL-024)
FormatBispecific antibody (BsAb)
TargetsPD-L1 (checkpoint inhibition) + 4-1BB (costimulatory activation)
IndicationFirst-line esophageal squamous cell carcinoma (ESCC)
Patient PopulationFirst-line (previously untreated) ESCC
MilestoneFirst patient dosed (March 2026)
SponsorNanjing Leads Biolabs (HKG: 9887)

Regulatory Designations & Prior Evidence

DesignationRegionIndication ContextStrategic Value
Breakthrough Therapy Designation (BTD)ChinaNSCLC, SCLC, extrapulmonary NECAccelerated NMPA review pathway; validation of clinical significance
Orphan Drug Designation (ODD)U.S.Rare cancers (SCLC, NEC)7-year market exclusivity; tax incentives; waiver fees
Fast Track DesignationU.S.—Rolling review; priority FDA engagement
Orphan Drug Designation (ODD)European Union—10-year market exclusivity; protocol assistance

Prior Clinical Performance (FIC/BIC Potential):

  • Non-small cell lung cancer (NSCLC): Phase II/registrational trials ongoing
  • Small cell lung cancer (SCLC): Registrational-stage development
  • Extrapulmonary neuroendocrine carcinoma (NEC): Phase II efficacy signals

Mechanism of Action & Differentiation

ComponentFunctionTherapeutic Synergy
PD-L1 ArmBlocks PD-1/PD-L1 interaction; restores T-cell recognition of tumor cellsCheckpoint inhibition reverses immune evasion
4-1BB ArmCostimulatory receptor activation on T-cells; enhances proliferation, survival, and effector functionConditional activation only when PD-L1 engagement occurs → tumor-localized immune stimulation
Bispecific FormatDual targeting in single moleculeReduced systemic 4-1BB agonism toxicity vs. monotherapy; enhanced tumor-specific immune activation

Competitive Positioning vs. Standard of Care:

ParameterOpamtistomigChemo + PD-1 (Current 1L ESCC)Advantage
MechanismDual checkpoint + costimulationChemotherapy + single checkpointPotential for superior ORR and durability
Safety ProfileConditional 4-1BB activationChemo-related myelosuppressionReduced hematologic toxicity
Efficacy SignalFIC/BIC potential in prior tumorsModest survival benefitPotential for paradigm shift in ESCC immunotherapy

Market Context & Strategic Value

FactorImplication
ESCC BurdenChina accounts for 50%+ of global ESCC cases; 300,000+ annual diagnoses; 5-year survival <20% in advanced disease
Standard of Care EvolutionPD-1 + chemotherapy approved (2020-2022); bispecifics represent next-generation immunotherapy
First-Line PositioningFront-line ESCC approval would capture largest addressable population; second-line salvage therapy limited efficacy
Global ExpansionU.S./EU ODD/FTD enables parallel development; potential for simultaneous China-Western registration
Valuation ImpactHKG: 9887 shares expected to benefit from Phase II milestone; BTD validation supports premium multiples

Development Outlook

  • Phase II Design: Single-arm or randomized vs. chemo-PD-1 combination; primary endpoint ORR with PFS/OS secondary
  • Biomarker Strategy: PD-L1 expression, TMB, and immune infiltrate analysis to identify responder populations
  • Combination Potential: Future chemo-PD-1-opamtistomig triplet studies planned
  • Regulatory Pathway: China NDA 2027-2028 contingent on Phase II data; U.S. BLA 2028-2029 via ODD/FTD accelerated track

Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and competitive positioning for opamtistomig in esophageal squamous cell carcinoma. Actual results may differ due to trial outcomes, competitive dynamics with PD-1 combinations, and manufacturing scale-up challenges.-Fineline Info & Tech

2026030600400_cDownload

Related Post

Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Fineline Cube
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube
Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Fineline Cube

You Missed

Company Drug

Bristol-Myers Squibb’s Sotyktu Wins FDA Label Extension – TYK2 Inhibitor Expands to Psoriatic Arthritis

Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Company Drug

Hengrui’s Adebrelimab Wins NMPA Approval for Two Perioperative Cancer Trials – PD-L1/CTLA-4 Combo Targets Rectal and Gastric/GEJ Cancers

Company Drug

Leads Biolabs’ Opamtistomig Enters Phase II in First-Line Esophageal Cancer – PD-L1/4-1BB Bispecific with BTD/ODD Designations